Month: May 2025
-
UPC Court of Appeal makes UK judge feel even better about his decision: Alexion v. Amgen & Samsung Bioepis
Mr Justice Meade of the High Court of Justice for England & Wales would have reached the same decision anyway, but likes the fact that the UPC CoA interpreted the claim language in the same way.
-
Top Chinese court declines to transfer Huawei v. MediaTek SEP cases to Beijing or to separate claims against different defendants
MediaTek unsuccessfully appealed: its jurisdictional challenge to Huawei’s SEP enforcement actions in China has failed definitively.
-
TCL, Panasonic expand participation in Via Licensing Alliance ATSC 3.0 patent pool, Korea Electronics Technology Institute brand new member
Via LA today welcomed TCL, already a long-term licensee, as a licensor, after Panasonic and the Korea Electronics Technology Institute also joined the pool as a licensee and licensor, respectively, earlier this month.
-
Pendulum swings back in favor of Fintiv in payment-system patent infringement dispute with Apple
The United States Court of Appeals for the Federal Circuit has reversed a Western District of Texas grant of summary judgment in a dispute between Fintiv and Apple, reviving Fintiv’s infringement claims and remanding them for trial.
-
UPC Roundup (1 week): second medical use; evidence gathering through on-site experiments; various new cases
This is a summary of developments in and around the Unified Patent Court (UPC) in the week since our May 10, 2025 UPC Roundup. Only a few noteworthy things happened. 1. CoA: confidentiality concerns don’t warrant splitting up case In Corning v. Hisense, TCL and LG, Standing Judge (of the Court of Appeal (CoA)) Patricia Rombach affirmed…
-
Illumina sues Element Biosciences in Delaware over gene sequencing patents
While this is Illumina’s first official suit against Element Biosciences, the latter has already faced challenges over its gene sequencing technology based on prior art from Illumina’s assets.
-
Two U.S. pharma patent disputes fail to make it to trial: Alnylam concedes first round of litigation against Pfizer, BioNTech in COVID vaccine war, Nexus obtains summary judgment of invalidity
While Alnylam has dropped its patent infringement dispute against Pfizer, BioNTech, and Ingenus Pharmaceuticals has failed to take its cancer dispute to trial, both cases are subject to appeal.
-
10x Genomics and Bruker (NanoString) end global patent dispute
The UPC’s first major patent dispute has ended after the companies signed a global cross-license patent agreement.
-
New study: Huawei leads WiFi 7 SEP ownership, Ericsson sole European patentee
A report on WiFi 7 SEP ownership published by GreyB today has found European patentees lag way behind those in Mainland China and the U.S., with Ericsson being the only patentee mentioned from the region.
-
UPC Dusseldorf issues first decision on second medical use, hands win to Amgen in cholesterol patent dispute against Sanofi
The Dusseldorf Local Division has clarified how the UPC deals with second medical use in patent infringement proceedings, including considering the extent or significance of the allegedly infringing use, and whether an entity is “positively” or “negatively” influencing a market by encouraging infringement, or preventing a product from being used for patented use.